Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer

被引:28
作者
Pederson, Aaron W. [2 ]
Salama, Joseph K. [1 ]
Witt, Mary Ellen [2 ]
Stenson, Kerstin M. [3 ,4 ]
Blair, Elizabeth A. [3 ,4 ]
Vokes, Everett E. [2 ,3 ,5 ]
Haraf, Daniel J. [2 ,3 ]
机构
[1] Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC 27710 USA
[2] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[3] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
[4] Univ Chicago, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA
[5] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2011年 / 34卷 / 04期
关键词
intensity-modulated radiotherapy; IMRT; oral cavity cancer; chemoradiotherapy; organ preservation; SQUAMOUS-CELL-CARCINOMA; PERFORMANCE STATUS SCALE; LOCALLY ADVANCED HEAD; QUALITY-OF-LIFE; PHASE-II TRIAL; NECK-CANCER; CONCOMITANT CHEMORADIOTHERAPY; RADIATION-THERAPY; INDUCTION CHEMOTHERAPY; FUNCTIONAL ASSESSMENT;
D O I
10.1097/COC.0b013e3181e8420b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To report outcomes of oral cavity cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy (chemoIMRT). Methods: Between 2001 and 2004, 21 patients with oral cavity squamous cell carcinoma underwent definitive chemoIMRT. Sites included were oral tongue (n = 9), floor of mouth (n = 6), buccal mucosa (n = 3), retromolar trigone (n = 2), and hard palate (n = 1). Most had stage III-IV disease (n = 20). The most common regimen was 5 days infusional 5-fluorouracil (600 mg/m(2)/d x 5 days), hydroxyurea (500 mg, PO BID), and 1.5 Gy twice-daily irradiation to 72 to 75 Gy. Results: The median follow-up for surviving patients was 60 months. Treatment failure occurred as follows: local-1, regional-1, and distant metastases-2. The 2- and 5-year estimates of locoregional progression-free survival, disease-free survival, and overall survival were 90% and 90%, 71% and 71%, and 76% and 76%, respectively. Late complications included osteoradionecrosis (3 patients, 14%). Conclusions: Concurrent chemoIMRT results in promising locoregional control for oral cavity squamous cell carcinomas with acceptable toxicity.
引用
收藏
页码:356 / 361
页数:6
相关论文
共 41 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer [J].
Ang, KK ;
Trotti, A ;
Brown, BW ;
Garden, AS ;
Foote, RL ;
Morrison, WH ;
Geara, FB ;
Klotch, DW ;
Goepfert, H ;
Peters, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03) :571-578
[3]  
BALOGH JM, 1989, J OTOLARYNGOL, V18, P245
[4]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[5]  
Bourhis J, 2004, J CLIN ONCOL, V22, p489S
[6]   THE HEAD AND NECK RADIOTHERAPY QUESTIONNAIRE - A MORBIDITY QUALITY-OF-LIFE INSTRUMENT FOR CLINICAL-TRIALS OF RADIATION-THERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER [J].
BROWMAN, GP ;
LEVINE, MN ;
HODSON, DI ;
SATHYA, J ;
RUSSELL, R ;
SKINGLEY, P ;
CRIPPS, C ;
EAPEN, L ;
GIRARD, A .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :863-872
[7]   A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck [J].
Budach, W ;
Hehr, T ;
Budach, V ;
Belka, C ;
Dietz, K .
BMC CANCER, 2006, 6 (1)
[8]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[9]   Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer [J].
Chao, KSC ;
Ozyigit, G ;
Tran, BN ;
Cengiz, M ;
Dempsey, JF ;
Low, DA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (02) :312-321
[10]   High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial [J].
Cohen, Ezra E. W. ;
Haraf, Daniel J. ;
List, Marcy A. ;
Kocheginsky, Masha ;
Mittal, Bharat B. ;
Rosen, Fred ;
Brockstein, Bruce ;
Williams, Rosalyn ;
Witt, Mary Ellyn ;
Stenson, Kerstin M. ;
Kies, Merrill S. ;
Vokes, Everett E. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3438-3444